Inmune Bio annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Inmune Bio Debt-to-Equity Ratio Growth & History (INMB)
Inmune Bio's debt-to-equity ratio was 0.04 for fiscal 2025.
View full Inmune Bio company overviewInmune Bio annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.04 | 0.03 | +267.40% |
| 2024 | 2024-12-31 | 0.01 | −0.27 | −95.72% |
| 2023 | 2023-12-31 | 0.28 | 0.10 | +55.04% |
| 2022 | 2022-12-31 | 0.18 | −0.02 | −8.32% |
| 2021 | 2021-12-31 | 0.20 | 0.19 | +2223.43% |
| 2020 | 2020-12-31 | 0.01 | 0.00 | +18.63% |
| 2019 | 2019-12-31 | 0.01 | — | — |
Inmune Bio quarterly debt-to-equity ratio
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.07 | 0.05 | +341.65% |
| Q1 2026 | 2026-03-31 | 0.08 | — | — |
| Q4 2025 | 2025-12-31 | 0.04 | — | — |
| Q3 2025 | 2025-09-30 | 0.04 | −0.03 | −43.50% |
| Q2 2025 | 2025-06-30 | 0.02 | −0.13 | −89.56% |
| Q3 2024 | 2024-09-30 | 0.08 | −0.22 | −74.62% |
| Q2 2024 | 2024-06-30 | 0.15 | −0.16 | −51.28% |
| Q1 2024 | 2024-03-31 | 0.28 | −0.00 | −0.31% |
| Q4 2023 | 2023-12-31 | 0.28 | 0.10 | +55.04% |
| Q3 2023 | 2023-09-30 | 0.30 | 0.05 | +20.01% |
| Q2 2023 | 2023-06-30 | 0.31 | 0.08 | +36.36% |
| Q1 2023 | 2023-03-31 | 0.28 | 0.07 | +35.39% |
| Q4 2022 | 2022-12-31 | 0.18 | −0.02 | −8.32% |
| Q3 2022 | 2022-09-30 | 0.25 | 0.08 | +44.19% |
| Q2 2022 | 2022-06-30 | 0.23 | −0.11 | −32.77% |
| Q1 2022 | 2022-03-31 | 0.21 | 0.21 | +9431.06% |
| Q4 2021 | 2021-12-31 | 0.20 | 0.19 | +2223.43% |
| Q3 2021 | 2021-09-30 | 0.17 | 0.17 | +4422.65% |
| Q2 2021 | 2021-06-30 | 0.34 | 0.33 | +4669.41% |
| Q1 2021 | 2021-03-31 | 0.00 | −0.01 | −71.62% |
| Q4 2020 | 2020-12-31 | 0.01 | 0.00 | +18.63% |
| Q3 2020 | 2020-09-30 | 0.00 | −0.00 | −50.08% |
| Q2 2020 | 2020-06-30 | 0.01 | 0.00 | +2.17% |
| Q1 2020 | 2020-03-31 | 0.01 | — | — |
| Q4 2019 | 2019-12-31 | 0.01 | — | — |
| Q3 2019 | 2019-09-30 | 0.01 | — | — |
| Q2 2019 | 2019-06-30 | 0.01 | — | — |
Inmune Bio debt-to-equity ratio trends
Over the last five fiscal years, Inmune Bio's debt-to-equity ratio increased from 0.01 to 0.04, a change of 0.04. The latest reported quarter, Q2 2026, shows 0.07.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inmune Bio source filings ↗